Literature DB >> 1706402

Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human IL-2.

H P Fell1, M A Gayle, L Grosmaire, J A Ledbetter.   

Abstract

A genetic construct was created incorporating gene fragments encoding the H chain V region of the human carcinoma specific antibody L6, the CH1 domain of human IgG1, a linker region, and human IL-2. This construct was cotransfected with a chimeric L6 L chain construct into the murine myeloma cell line Ag8.653 for expression. First round clones produced the fusion protein at an estimated 5 to 10 micrograms/ml based on idiotypic reactivity. Dual binding activity was demonstrated through specific interaction with the L6 Ag on human tumor cells and the IL-2R on activated human T cells. The IL-2 portion of the molecule was shown to support the growth of the IL-2-dependent T cell line CTLL2, and the qualitative nature of the IL-2 signal was found to be the same as rIL-2 with respect to induction of tyrosine-phosphorylation of intracellular protein substrates. Tumor cells coated with the fusion protein were shown to cause T cell proliferation and the presence of the fusion protein was found to enhance cell-mediated destruction of human tumor cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706402

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-10-11       Impact factor: 16.971

2.  High efficient mammalian expression and secretion of a functional humanized single-chain Fv/human interleukin-2 molecules.

Authors:  Yue-Chun Shen; Xue-Hao Wang; Xiao-Ming Wang; Zao-Lai Chen; Xi-Ping Shen; Chao-Chen Zhao; Jun Li
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

3.  A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice.

Authors:  H Sabzevari; S D Gillies; B M Mueller; J D Pancook; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

4.  A recombinant single-chain antibody interleukin-2 fusion protein.

Authors:  P Savage; A So; R A Spooner; A A Epenetos
Journal:  Cell Biophys       Date:  1993 Jan-Jun

5.  Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

Authors:  S D Gillies; E B Reilly; K M Lo; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

6.  Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.

Authors:  J C Becker; J D Pancook; S D Gillies; J Mendelsohn; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

Review 7.  Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.

Authors:  A P Zbar; N R Lemoine; M Wadhwa; H Thomas; D Snary; W A Kmiot
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

8.  A recombinant single chain antibody interleukin-2 fusion protein.

Authors:  P Savage; A So; R A Spooner; A A Epenetos
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

9.  A circularly permuted recombinant interleukin 4 toxin with increased activity.

Authors:  R J Kreitman; R K Puri; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 12.779

Review 10.  Utilizing Immunocytokines for Cancer Therapy.

Authors:  Erin Runbeck; Silvia Crescioli; Sophia N Karagiannis; Sophie Papa
Journal:  Antibodies (Basel)       Date:  2021-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.